Tissue Inhibitor of Metalloproteinase-2 Polymorphisms and Risk for HIV-Associated Neurocognitive Disorder
Table 5
Frequency distribution of TIMP-2 (-418G/C and 303G/A) polymorphisms in HIV disease stages of HIV patients (CD4 <200, 201-350, and >350) and healthy controls.
Genotypes TIMP-2 -418G/C
Healthy controls () (%)
Early HIV disease stage
Intermediate HIV disease stage
Advanced HIV disease stage
(%)
OR ()
(%)
OR ()
(%)
OR ()
GG
118 (76.6%)
35 (59.3%)
Reference
20 (74.1%)
Reference
12 (85.7%)
Reference
GC
34 (22.1%)
14 (23.7%)
1.35 (0.46)
4 (14.8%)
0.70 (0.57)
2 (14.3%)
0.65 (0.60)
CC
2 (1.3%)
10 (16.9%)
14.51 (0.002)
3 (11.1%)
14.63 (0.01)
0 (0.0%)
NS
Genotypes TIMP-2 303G/A
Healthy controls () (%)
Early HIV disease stage
Intermediate HIV disease stage
Advanced HIV disease stage
(%)
OR ()
(%)
OR ()
(%)
OR ()
GG
106 (68.8%)
38 (68.8%)
Reference
21 (77.8%)
Reference
12 (85.7%)
Reference
GA
45 (29.2%)
20 (33.9%)
1.39 (0.36)
6 (22.2%)
0.86 (0.77)
2 (14.3%)
0.50 (0.39)
AA
3 (1.9%)
1 (1.7%)
0.67 (0.76)
0 (0.0%)
NS
0 (0.0%)
NS
= number of subjects, (%) = frequency of subjects; odds ratios and 95% CIs were derived from logistic regression models comparing the homozygous wild-type genotype (GG genotype for TIMP-2 -418G/C and 303G/A was taken as reference) with other genotypes. Significant values () and related OR have been shown in bold.
